SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
HanAll BioPharma Co., Ltd. Release: U.S. IND Accepted by the FDA in Support of the Clinical Development HL 007, a Unique Fixed Dose Combination to Treat Cardiovascular Disease